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incidence
In 2002, the crude incidence rates of carcinoma of the head and
neck (ICD, 10th revision C00–C10, C12–C14, C32) in Europe
were 36/100 000/year in the male population and 7/100 000/
year for females, while the corresponding mortality rates were
18 and 3/100 000/year. On the European scale, head and neck
cancer accounts for 139 000 new cases per year. More than 90%
of head and neck malignancies are squamous cell carcinomas.
In Europe the relative survival rate for head and neck cancer
patients was 72% at 1 year and 42% at 5 years in adults. Five-
year survival was higher in women (51%) than men (39%). The
effect of age on survival is marked. Survival at 5 years was 54%
for the youngest age group (15–45 years) and 35% in the oldest
group of patients (‡75 years old).
diagnosis
Pathological diagnosis should be made according to the World
Health Organization classification from a surgical biopsy
sample.
Routine staging includes physical examination, chest X-ray,
head and neck endoscopy, and head and neck computed
tomography (CT) scan or magnetic resonance imaging (MRI).
MRI is the preferable staging procedure for every tumour
subsite except laryngeal and hypopharyngeal cancers. A
thoracic CT scan may be performed to rule out metastatic
disease and or second lung primaries. The role of 2-[18F]fluoro-
2-deoxy-D-glucose positron emission tomography (FDG-PET
or PET-CT) at staging is under investigation. In this context it
can be stated that in general PET has a lower specificity than
sensitivity, and that it may be more useful for staging the
metastasis or synchronous tumours than the neck node.
Squamous cell head and neck cancer should be staged
according to the TNM system and grouped into categories
shown in Table 1. According to the seventh AJCC classification
T4 tumours are subdivided into T4a moderately advanced and
T4b very advanced. Stage IV is subdivided into stages IVa and
IVb accordingly, and stage IVc for metastatic disease.
Modern risk assessment should also include that for
oropharyngeal tumour, whether the disease is HPV related,
together with the smoking habits.
treatment plan
A multidisciplinary treatment schedule should be established in
all cases. The patient’s nutritional status must be corrected and
maintained. Dental rehabilitation is indicated before
radiotherapy. Treatment depends on primary tumour location
and extension. Rare squamous head and neck cancer
originating from paranasal sinuses and nasopharynx are usually
excluded from trial treatment series supporting evidence-based
recommendations, so they are excluded from these clinical
recommendations. In early stage (I–II), either conservative
surgery or radiotherapy (external radiotherapy or
brachytherapy) gives similar loco-regional control. However,
this is based only on retrospective studies as there are no
randomized trials available for reference. Modern radiotherapy
treatment should include 3D conformal radiation therapy or
intensity-modulated radiation therapy (IMRT).
Standard options for locally advanced stage III and IV
tumours are: surgery including reconstruction plus
postoperative radiotherapy and, for those patients found at
surgery to have high-risk features (nodal extracapsular
extension and/or R1 resection), post-operative
chemoradiotherapy (CRT) with single-agent platinum [I, A].
However, in resectable patients, when the anticipated
functional outcome and/or the prognosis is so poor that
mutilating surgery is not justified, combined concomitant
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chemoradiation is preferred. Combined concomitant
chemoradiation is also the standard treatment in non-
resectable patients [I, A]. Radiotherapy given concomitantly
with cetuximab has demonstrated a higher response rate, longer
disease-free progression and longer overall survival versus
radiotherapy alone [II, B]. There is no formal comparison
between the combination of radiotherapy with cisplatin or
cetuximab. In this context the therapeutic decision is difficult
to take. However, it should be considered that results of
concomitant chemoradiation are based on thousands of
patients, that this combination is associated with significant
toxicity and that its efficacy in the elderly population is
questioned. On the other hand results of cetuximab + radiation
are based on 200 patients, the magnitude in effect was similar
or even better than that achieved by concomitant
chemoradiation, it proved to be less toxic and the benefit in the
elderly subgroup is also questioned.
The role of induction chemotherapy (ICT) has been
reconsidered since the introduction of taxane–platinum-based
(TPF) combinations that have proved to be superior to
platinum–fluorouracil PF schedule in loco-regionally advanced
disease [I, A]. However, at present, induction chemotherapy is
not considered standard treatment in advanced disease. ICT
followed by RT-CT (so-called sequential CT-RT) is still under
evaluation. The overall toxicity of this approach can be
substantial thus compromising the final result.
TPF induction chemotherapy followed by radiotherapy in
responsive patients is an option for organ preservation in
advanced larynx and hypopharynx cancer in patients otherwise
requiring total laryngectomy [II, A]. CRT is another option. In
one randomized trial, concurrent CRT achieved higher larynx
preservation rates in the first 2 years after treatment completion
but this was not associated with improved survival over either
ICT followed by radiation in responsive patients or
radiotherapy alone [II A]. The choice between either an ICT-
based or a CRT-based organ-preserving protocol depends on
various factors (anatomical subsite, foreseable compliance/
tolerance to treatment, perfomance status, etc.). In addition,
not every patient and tumour presentation is suitable for organ
preservation. Patients with massive larynx cartilage invasion
should be excluded from this approach. Whether based on ICT
or CRT, these treatment options have no negative impact on
disease-free or overall survival, due to the successful salvage
treatment with surgery [II, A], although in general those
patients undergoing such treatments tend to have a reduction
in distant metastasis.
local, regional and metastatic
recurrence
In selected cases of localized recurrence, surgery (if operable) or
re-irradiation can be considered. For most patients palliative
chemotherapy is the standard option. First-line option for fit
patients should include the combination of cetuximab with
cisplatin or carboplatin plus 5-fluorouracil (PF). It resulted in
longer survival than PF alone [II, A]. In patients for which
polychemotherapy tolerability is anticipated to be poor
monochemotherapy should be used. Weekly methotrexate may
be considered as the accepted treatment [I, A]. Since there is no
comparison between taxanes and methotrexate as monotherapy
it is difficult to state whether taxanes are useful in this context.
Cetuximab alone has a favourable toxicity profile with activity
that is comparable to methotrexate alone.
follow-up
Treatment response should be evaluated by clinical
examination and CT scan or MRI of head and neck depending
on the initial procedure. FDG-PET (or PET-CT) may be used
to evaluate the response to radiotherapy or concomitant CRT
at the neck level and decide upon the usefulness of a neck node
dissection. The aim of follow-up is the early detection of
potentially curable loco-regional recurrence and second
tumours. Physical examination along with radiological imaging
in the case of suspicion of recurrence should be included in
the follow-up. FDG-PET scanning may be useful in the
presence of doubtful findings, particularly after combined
chemoradiation. In such situations its negative predictive value
is superior to the positive one. At this time, special attention
should be paid to the treatment sequelae that include
swallowing and respiratory impairment. Chest X-ray may be
included on a yearly basis. Evaluation of thyroid function
(serum thyroid-stimulating hormone—TSH—levels) in
patients with irradiation to the neck is recommended at 1, 2
and 5 years.
note
Levels of Evidence [I–V] and Grades of Recommendation [A–
D] as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts.
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